Pembrolizumab after partial breast radiation for early triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether giving the immunotherapy drug pembrolizumab (Keytruda) after partial breast radiation helps treat early-stage triple-negative breast cancer. It is for people whose tumors have a 'cold' immune environment, meaning they don't have many immune cells inside them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years or older and have been diagnosed with stage II or higher triple-negative breast cancer.
- Your tumor has a 'cold' immune environment with low levels of immune cells (TILs less than 30%) and low PD-L1 protein (CPS less than 10).
- You have not had breast cancer before, and you have never had chemotherapy or radiation therapy.
- You are scheduled to receive radiation only to part of your breast, not the whole breast.
- You have an ECOG performance status of 0 to 2, meaning you are up and able to care for yourself at least half the day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests pembrolizumab (an immune medicine) to see how it affects the tumor and its surroundings in triple-negative breast cancer. It’s mainly looking at safety and early signs of benefit, especially in a limited, early-stage breast tumor.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
This trial tests if continuing pembrolizumab after surgery can help prevent breast cancer from coming back in people with triple-negative breast cancer who still had some cancer after initial chemo and pembrolizumab before surgery.
This trial is for people with early triple-negative breast cancer who had a strong response to chemotherapy combined with pembrolizumab before surgery. It aims to find the best way to continue using pembrolizumab after surgery to reduce the risk of cancer coming back.
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Hear when a new Triple-Negative Breast Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.